[DEBUG-WINDOW 처리영역 보기]
즐겨찾기  |  뉴스레터  |  오늘의 정보  |  e브릭몰e브릭몰 회원가입   로그인
BRIC홈 한국을 빛내는 사람들
스폰서배너광고 안내  배너1 배너2 배너3 배너4
전체보기 추천논문 상위피인용논문 인터뷰 그이후 한빛사통계
최윤홍 (Yoon Hong Choi) 저자 이메일 보기
Public Health England
조회 169  인쇄하기 주소복사 트위터 공유 페이스북 공유 
Estimated impact of revising the 13-valent pneumococcal conjugate vaccine schedule from 2+1 to 1+1 in England and Wales: A modelling study
열기 Authors and Affiliations


In October 2017, the United Kingdom Joint Committee on Vaccination and Immunisation (JCVI) recommended removal of one primary dose of the 13-valent pneumococcal conjugate vaccine (PCV13) from the existing 2+1 schedule (2, 4, 12 months). We conducted a mathematical modelling study to investigate the potential impact of a 1+1 (3, 12 month) schedule on invasive pneumococcal disease (IPD) and pneumococcal community-acquired pneumonia (CAP). Our results and those from a 1+1 immunogenicity study formed the key evidence reviewed by JCVI.

Methods and findings
We developed age-structured, dynamic, deterministic models of pneumococcal transmission in England and Wales to describe the impact on IPD of 7-valent PCV (PCV7; introduced in 2006) and PCV13 (introduced in 2010). Key transmission and vaccine parameters were estimated by fitting to carriage data from 2001/2002 and post-PCV IPD data to 2015, using vaccine coverage, mixing patterns between ages, and population data. We considered various models to investigate potential reasons for the rapid increase in non-PCV13 (non-vaccine serotype [NVT]) IPD cases since 2014. After searching a large parameter space, 500 parameter sets were identified with a likelihood statistically close to the maximum and these used to predict future cases (median, prediction range from 500 parameter sets). Our findings indicated that the emergence of individual NVTs with higher virulence resulting from ongoing replacement was likely responsible; the NVT increase was predicted to plateau from 2020. Long-term simulation results suggest that changing to a 1+1 schedule would have little overall impact, as the small increase in vaccine-type IPD would be offset by a reduction in NVT IPD. Our results were robust to changes in vaccine assumptions in a sensitivity analysis. Under the base case scenario, a change to a 1+1 schedule in 2018 was predicted to produce 31 (6, 76) additional IPD cases over five years and 83 (−10, 242) additional pneumococcal-CAP cases, with together 8 (−2, 24) additional deaths, none in children under 15 years. Long-term continuation with the 2+1 schedule, or changing to a 1+1, was predicted to sustain current reductions in IPD cases in under-64-year-olds, but cases in 65+-year-olds would continue to increase because of the effects of an aging population. Limitations of our model include difficulty in fitting to past trends in NVT IPD in some age groups and inherent uncertainty about future NVT behaviour, sparse data for defining the mixing matrix in 65+-year-olds, and the methodological challenge of defining uncertainty on predictions.

Our findings suggest that, with the current mature status of the PCV programme in England and Wales, removing one primary dose in the first year of life would have little impact on IPD or pneumococcal CAP cases or associated deaths at any age. A reduction in the number of priming doses would improve programmatic efficiency and facilitate the introduction of new vaccines by reducing the number of coadministered vaccines given at 2 and 4 months of age in the current UK schedule. Our findings should not be applied to other settings with different pneumococcal epidemiology or with immature programmes and poor herd immunity.

- 형식: Research article
- 게재일: 2019년 07월 (BRIC 등록일 2019-07-08)
- 연구진: 국외연구진
- 분야: Medicine
전장 염기서열 분석을 통한 폐선암의 구조 변이 규명[Cell]
발표: 박성열 (KAIST)
일자: 2019년 7월 17일 (수) 오후 02시 (한국시간)
언어: 한국어
참석자 접수신청하기

  댓글 0
Springer Nature
최윤홍 님 전체논문보기 >
관련분야 논문보기

Google (by Yoon Hong Choi)
Pubmed (by Yoon Hong Choi)
프리미엄 Bio일정 Bio일정 프리미엄 안내
BRIC X ThermoFisher Scientific과 함께하는 사이언스 바캉스
BRIC X ThermoFisher Scientific과 함께하는 사이언스 바캉스
사전접수: ~2019.07.26
날짜: 2019.08.07~08
장소: 강남구 광평로 281, 수서오피스빌딩 11층 (수서역 3번 출구)
2019 부산대학교 의학전문대학원 의과학과 Open Lab
2019 부산대학교 의학전문대학원 의과학과 Open Lab
사전접수: ~2019.08.20
날짜: 2019.08.29
장소: 부산대학교 의학전문대학원(양산캠퍼스) 통합행정동 116호
[BRIC Webinar]Microbiome 분석의 정확도와 재현성 향상 방법-경신과학(Zymo Research)
[대졸자 대상]바이오QC 실무과정 7기 모집
[대졸자 대상]바이오QC 실무과정 7기 모집
날짜: 2019.09.02~06.12
장소: 성남시 분당구 황새울로 329번길 5
(고용부 재직자 무료과정) 임상시험 관리 과정
(고용부 재직자 무료과정) 임상시험 관리 과정
날짜: 2019.07.17~19
장소: 경기도 성남시 분당구 판교로289번길 20 스타트업캠퍼스 2층 세미나실
(고용부 재직자 무료과정)바이오/의약분야 계약 및 협상의 이해과정
(고용부 재직자 무료과정)바이오/의약분야 계약 및 협상의 이해과정
날짜: 2019.07.24~26
장소: 경기도 성남시 분당구 판교로289번길 20 스타트업캠퍼스 2층 세미나실
생물정보 빅데이터 분석 UCC 공모전
생물정보 빅데이터 분석 UCC 공모전
날짜: 2019.08.22
주관: K-Genome 유전체빅데..
한빛사 홈  |  한빛사FAQ  |  한빛사 문의 및 제안
 |  BRIC소개  |  이용안내  |  이용약관  |  개인정보처리방침  |  이메일무단수집거부
Copyright © BRIC. All rights reserved.  |  문의 member@ibric.org
트위터 트위터    페이스북 페이스북   유튜브 유튜브    RSS서비스 RSS